Investors in Science

MedSciences Capital (MSC) is a dedicated venture capital provider focused on supporting early- and mid-stage companies at the forefront of developing innovative products in the healthcare and life sciences sectors. With a mission to drive advancements in medical technologies and healthcare solutions, MedSciences Capital strategically invests in companies poised to make significant impacts on patient care and industry standards. Their investment approach combines financial support with strategic guidance and operational expertise, helping entrepreneurs navigate challenges and scale their innovations effectively. MSC's portfolio spans a wide range of healthcare innovations, including medical devices, biotechnology advancements, pharmaceuticals, and digital health solutions. By fostering partnerships and leveraging their extensive network, MedSciences Capital plays a crucial role in accelerating the development and commercialization of groundbreaking healthcare technologies that address global health challenges.

Granpool Innovative Investments is a trusted partner for entrepreneurs, dedicated to fostering innovation and growth in early-stage companies. With a focus on cutting-edge technologies and disruptive business models, Granpool provides essential capital and strategic support to startups across various industries. Their investment approach is characterized by a deep commitment to collaboration, working closely with founders to navigate challenges and seize opportunities. By leveraging their extensive network and expertise, Granpool empowers entrepreneurs to scale their businesses and achieve long-term success. The firm's dedication to driving impactful change ensures that their portfolio companies are well-positioned to lead in their respective markets, contributing to a more dynamic and forward-thinking business landscape. Through active partnership and unwavering support, Granpool Innovative Investments helps shape the future of innovation.

Boundary Capital Partners LLP is a venture capital firm specializing in early-stage growth companies, primarily within the technology sector. By offering both financial investment and hands-on support, Boundary Capital Partners helps innovative tech startups achieve their growth potential. Their investment approach combines capital with strategic guidance, leveraging their expertise and network to drive business success. Committed to fostering technological advancement, Boundary Capital Partners partners with visionary entrepreneurs to build the next generation of market-leading companies.

Advent Life Sciences is a venture capital firm dedicated to investing in life sciences businesses. Focusing on innovative companies in biotechnology, pharmaceuticals, medical devices, and diagnostics, Advent Life Sciences supports the development of breakthrough technologies and therapies. By providing capital and strategic expertise, the firm helps entrepreneurs navigate the complexities of the life sciences sector, accelerating the path from research to market. Advent Life Sciences is committed to advancing healthcare solutions that improve patient outcomes and address unmet medical needs globally.

NetScientific PLC (AIM: NSCI), we are a deep tech and life sciences venture capital investment group with a diverse international portfolio of innovative companies. Based in London, United Kingdom, our focus is on identifying, investing in, and nurturing high-growth businesses both locally and globally. Our approach involves adding significant value through proactive portfolio management, guiding companies towards key value inflection points, and achieving investment returns through strategic liquidity events. We distinguish ourselves by adopting a capital-light strategy, strategically managing our balance sheet, and syndicating investments through our wholly owned VC subsidiary, EMV Capital. This lean structure allows us to effectively support a broad portfolio while maintaining flexibility and scalability. Listed on AIM, a market operated by the London Stock Exchange, we uphold our commitment to transparency and accountability in all our investment operations.

MVM Life Science Partners, we are a specialized healthcare investment firm focused on early-stage and growth-stage companies in the life sciences sector. Founded in 1997 and headquartered in London, our firm invests globally in innovative biopharmaceuticals, medical technology, diagnostics, and digital health companies. Our approach combines deep sector expertise with strategic support to help our portfolio companies achieve their full potential. We have a strong track record of supporting groundbreaking therapies and technologies that make a significant impact on healthcare outcomes worldwide.

Winton Capital Management, we are a pioneering quantitative investment management firm founded in 1997 by Sir David Harding. Our approach is rooted in original research, rigorous statistical analysis, and deep market expertise, allowing us to develop and implement innovative investment strategies. We cater to a distinguished client base, including some of the world’s largest institutional investors, delivering customized solutions aimed at achieving consistent performance across diverse market conditions. Headquartered in London, our global presence enables us to manage substantial assets while continually advancing our quantitative finance capabilities.

Ruffena Capital specializes in financing and capital investment advisory services. As a trusted advisor, Ruffena Capital assists clients in navigating the complexities of capital raising and investment strategies. They provide tailored financial solutions and strategic guidance to businesses seeking growth capital, leveraging their expertise to optimize funding opportunities and drive sustainable business development. Ruffena Capital's commitment lies in facilitating successful capital transactions and fostering long-term partnerships with their clients.

Created over 20 years ago, Andera Partners is a major player in private company investments in France and internationally. Its teams manage over €3.6 billion in investments in life sciences (Andera Life Sciences), growth and buyout capital (Andera MidCap, Andera Expansion, Andera Croissance, Andera Co-Invest), sponsorless transactions (Andera Acto) and ecological transition (Andera Infra). Andera Partners’ mission is to work alongside companies and their managers to support them in achieving strong and sustainable growth. The quality of performance offered to our investors relies on a strong partnership between the entrepreneurs in our portfolio companies and our teams, based on shared values. Performance through collective engagement, the “Power of And”, constitutes Andera Partners’ DNA. Based in Paris, with offices in Antwerp and Munich, Andera Partners is wholly owned by its teams, which count nearly 95 professionals, of which 58 investment professionals. It is structured as a partnership and managed by a board of 10 partners. Responsible and committed, the management company regularly forms partnerships with non-profit sector entities and takes concrete action in the fight against global warming. Andera Partners has been certified carbon neutral since 2018.

McWin is a private investment firm that focuses on Food Tech, Life Science, Clean Tech, Mobility Space Tech, Digitalization, and Fintech.McWin is a private equity firm founded by Henry McGovern and Steven K. Winegar partnering with exceptional founders and CEOs daring sustainable disruption, principally in the foodservice and food technology sectors.

Mérieux Equity Partners is one of the most recognized and active European Investment firms in the Healthcare sector. We support the development and growth of high-potential companies from business launch to large scale deployment through capital investment and tailor-made support based on our strong sector expertise and international network. We are an agile investor with a flexible approach in terms of minority or majority stakes. Our main focus is partnering with and investing alongside management teams.

At Crédit Mutuel Innovation, our focus is on investing in innovative companies in deeptech, digital, and life sciences sectors, leveraging our €4 billion in capital under management. We provide equity tickets ranging from €1 to €20 million to support entrepreneurs in realizing their growth potential. Beyond financial investment, we foster long-term relationships by connecting companies within our ecosystems, recognizing that creating a world leader often requires sustained support over more than 5 years. This approach ensures sustainable development and mutual success for our portfolio companies and partners.